FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
Open Access
- 10 June 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (3) , 649-661
Abstract
Real‐World Evidence (RWE) is increasingly used in submissions to regulatory agencies and health technology assessment bodies (HTAbs) to support the efficacy and effectiveness of new medicines and indications. However, there is limited information on the RWE characteristics that impact its role in approval and reimbursement decisions. To investigate these characteristics, we developed FRAME: a Framework for Real‐world evidence Assessment to Mitigate Evidence uncertainties for efficacy/effectiveness. We compiled a list of medicinal product indications where RWE supported the efficacy of interventional trials or assessed effectiveness in observational settings. FRAME was applied to a prioritized subset of these submissions to authorities from North America, Europe, and Australia. For each product indication, we extracted information on characteristics describing the submission, clinical context, strength of evidence, and process factors from publicly available assessment reports. Of the 87 identified medicinal product indications, 15 were prioritized, covering 68 submissions and 76 RWE studies across 11 authorities in scope. Four main results emerged: (i) low granularity within assessment reports on the analyzed variables, limiting the learnings from analyzing them; (ii) variability in how RWE was assessed within and across regulatory agencies and HTAbs; (iii) a positive association between the proportion of positive comments from authorities on RWE studies and their impact on decision making. Particularly, a large effect size was consistently noted when RWE was considered primary evidence; and (iv) limited use of advanced RWE study designs. These findings support five recommendations to enhance shared learning on RWE, clarify its evidentiary value, and generate evidence to better support authorities' decision making.Keywords
This publication has 18 references indexed in Scilit:
- When can real‐world data generate real‐world evidence?Pharmacoepidemiology and Drug Safety, 2023
- Use of Real‐World Evidence in Neuroscience‐Related New Drug and Biologics License Applications for Novel TherapeuticsClinical Pharmacology & Therapeutics, 2023
- Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision MakingClinical Pharmacology & Therapeutics, 2022
- Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New TherapiesTherapeutic Innovation & Regulatory Science, 2022
- The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License ApplicationsClinical Pharmacology & Therapeutics, 2021
- Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019Clinical Pharmacology & Therapeutics, 2021
- Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?Clinical Pharmacology & Therapeutics, 2021
- Use of Real-World Evidence to Support FDA Approval of Oncology DrugsValue in Health, 2020
- Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countriesThe European Journal of Health Economics, 2017
- Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods studyHealth Policy, 2016